Wockhardt Limited, a leading pharmaceutical and biotechnology company, released its second-quarter financial results for the fiscal year 2024-25, showing significant growth across several critical areas. Revenue for Q2 rose by 7% year-on-year to ₹818 crore, up from ₹762 crore in the previous year, while EBITDA surged by an impressive 71%, reaching ₹139 crore compared to […]
Wockhardt Limited announced that its investigational drug Zaynich (Zidebactam/Cefepime) has successfully treated a complex case of bacterial meningitis caused by a pan-drug-resistant superbug under compassionate use. This breakthrough marks another instance where the novel antibiotic has proven its efficacy against critical infections, particularly those caused by multi-drug-resistant bacteria. The patient, a 64-year-old man with Type […]
